This inventor holds 5 USPTO granted patents and 7 published patent applications and 5 EPO patents. Top assignee: Genzyme Corporation. Active years: 2007-2021.
Location History:
- Hayward, CA (US) (2007 - 2016)
- Bridgewater, NJ (US) (2021)
Company Filing History:
Years Active: 2007-2021
Title: Michael A Lochrie: Innovator in AAV Virion Technology
Introduction
Michael A Lochrie is a notable inventor based in Hayward, CA (US). He has made significant contributions to the field of recombinant AAV (adeno-associated virus) technology. With a total of 5 patents to his name, Lochrie's work focuses on enhancing the efficacy and safety of AAV virions.
Latest Patents
One of Lochrie's latest patents is titled "AAV virions with decreased immunoreactivity and uses therefor." This patent describes methods for creating and utilizing recombinant AAV virions that exhibit decreased immunoreactivity. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates, which display reduced immunoreactivity compared to AAV-2. This innovation has the potential to improve therapeutic applications of AAV in gene therapy.
Career Highlights
Throughout his career, Lochrie has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Genzyme Corporation and Avigen, Inc. His experience in these organizations has contributed to his expertise in AAV technology and its applications.
Collaborations
Lochrie has collaborated with several professionals in his field, including Alejandra Elena Arbetman and Peter C Colosi. These collaborations have likely enriched his research and development efforts in AAV virion technology.
Conclusion
Michael A Lochrie's innovative work in the field of AAV technology demonstrates his commitment to advancing gene therapy solutions. His patents and collaborations reflect a significant contribution to the scientific community.